CDH1 and neoplasm: Thereby, it was suggested that EGCG may serve as a potential epigenetic modifier by altering the methylation status of genes encoding retinoic acid receptor beta (RARβ), cadherin 1 (CDH1), and death-associated protein kinase 1 (DAPK1) tumor suppressors to reactivate their expression [57].